{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:43:04Z","timestamp":1773456184204,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.exphem.2010.03.016","type":"journal-article","created":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T04:25:16Z","timestamp":1270182316000},"page":"462-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Circulating CD33 and its clinical value in acute leukemia"],"prefix":"10.1016","volume":"38","author":[{"given":"Adam","family":"Abdool","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hsiung","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marie","family":"Bruey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.03.016_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0959-440X(02)00375-5","article-title":"Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell\u2013cell interactions and signalling","volume":"12","author":"Crocker","year":"2002","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.exphem.2010.03.016_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.03.016_bib3","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1074\/jbc.274.17.11505","article-title":"The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2","volume":"274","author":"Taylor","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2010.03.016_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0301-472X(03)00044-4","article-title":"The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with the Syk and\/or ZAP-70 expression","volume":"31","author":"Balaian","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.03.016_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","article-title":"Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity","volume":"105","author":"Walter","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.03.016_bib6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.03.016_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.03.016_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/blood.V72.1.314.314","article-title":"Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen","volume":"72","author":"Peiper","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.03.016_bib9","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2010.03.016_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2010.03.016_bib11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3816\/CLM.2002.s.002","article-title":"CD33 as target for selective ablation of acute myeloid leukemia","volume":"2","author":"Bernstein","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.exphem.2010.03.016_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/10428190500126075","article-title":"CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives","volume":"46","author":"Sperr","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2010.03.016_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2401851","article-title":"Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines","volume":"14","author":"Naito","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.03.016_bib14","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2010.03.016_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.03.016_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"Van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.03.016_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.leu.2402749","article-title":"Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin","volume":"17","author":"Zwaan","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.03.016_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2003.00084.x","article-title":"Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia","volume":"71","author":"Candoni","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2010.03.016_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","article-title":"Differences in CD33 intensity between\u00a0various myeloid neoplasms","volume":"118","author":"Jilani","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.exphem.2010.03.016_bib20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.03.016_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190109057956","article-title":"A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma","volume":"41","author":"Khorana","year":"2001","journal-title":"Leuk Lymphoma"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10001311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10001311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:49Z","timestamp":1759566469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X10001311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0301472X10001311"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.03.016","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating CD33 and its clinical value in acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2010.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}